Gabapentin attenuates superior oblique myokymia.

Abstract

PURPOSE:

To investigate therapeutic effects of oral gabapentin therapy on superior oblique myokymia.

DESIGN:

Observational case series with measurement of visual acuity and eye movements before, during, and after therapy.

METHODS:

Two adult patients with superior oblique myokymia, refractory to other therapies, were treated with gabapentin orally after informed consent was obtained. Eye movements were measured using the magnetic search coil technique.

RESULTS:

Superior oblique myokymia completely resolved after starting gabapentin.

CONCLUSION:

Gabapentin may be an effective treatment for superior oblique myokymia; a double-blind study seems justified.

• Authors: Robert L Tomsak, Gregory S Kosmorsky, R John Leigh
• Journal: American journal of ophthalmology (Am J Ophthalmol) Vol. 133 Issue 5 Pg. 721-3 (May 2002) ISSN: 0002-9394 [Print] United States
• PMID: 11992881 (Publication Type: Case Reports, Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Acetates
• Amines
• Cyclohexanecarboxylic Acids
• Excitatory Amino Acid Antagonists
• gamma-Aminobutyric Acid
• Gabapentin

Topics

• Acetates (therapeutic use)
• Administration, Oral
• Adult
• Amines
• Cyclohexanecarboxylic Acids
• Diplopia (drug therapy, etiology)
• Excitatory Amino Acid Antagonists (therapeutic use)
• Eye Movements
• Female
• Gabapentin
• Humans
• Male
• Middle Aged
• Treatment Outcome
• Trochlear Nerve Diseases (complications, drug therapy)
• gamma-Aminobutyric Acid